Tempest Therapeutics Inc Financials
This page shows Tempest Therapeutics Inc (TPST) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
With no reported revenue, Tempest’s economics are driven by cash burn control and recurring external financing dependence.
FY2025 looked better on paper, with net loss improving to-$26.3M from-$41.8M in FY2024. But the business was not closer to self-funding: operating cash flow was still-$26.8M and year-end cash only$7.7M , which implies the smaller loss mostly came from reduced spending rather than from an operating engine that is beginning to pay for itself.
R&D fell below SG&A in FY2025, at
External funding remained necessary, but the inflow slowed to
Financial Health Signals
Tempest Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Tempest Therapeutics Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass.
Tempest Therapeutics Inc reported a net loss of $26.3M while operations used $26.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Tempest Therapeutics Inc reported an operating loss of $26.6M against $207K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Tempest Therapeutics Inc's EBITDA was -$26.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.8% from the prior year.
Tempest Therapeutics Inc reported -$26.3M in net income in fiscal year 2025. This represents an increase of 37.2% from the prior year.
Tempest Therapeutics Inc earned -$6.33 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Tempest Therapeutics Inc recorded an outflow of $26.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 19.8% from the prior year.
Tempest Therapeutics Inc held $7.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Tempest Therapeutics Inc's ROE was -393.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 175.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Tempest Therapeutics Inc invested $12.6M in research and development in fiscal year 2025. This represents a decrease of 55.7% from the prior year.
Tempest Therapeutics Inc reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
TPST Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $295K-54.8% | $653K+135.7% | $277K | $0 | $0 | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $790K-85.4% | $5.4M+140.2% | $2.2M | $0 | $0 | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$495K+89.6% | -$4.7M-140.8% | -$2.0M | $0 | $0 | N/A | N/A |
| R&D Expenses | N/A | $12.6M-55.7% | $28.5M+62.7% | $17.5M-22.3% | $22.5M+31.2% | $17.2M+19.3% | $14.4M-48.3% | $27.8M+93.0% | $14.4M-21.3% | $18.3M-15.3% | $21.6M+17.4% | $18.4M-15.4% | $21.8M+37.9% | $15.8M+149.9% | $6.3M | N/A |
| SG&A Expenses | N/A | $14.0M+3.1% | $13.6M+16.2% | $11.7M-3.7% | $12.1M+23.4% | $9.8M+100.0% | $4.9M-72.0% | $17.6M+102.0% | $8.7M-68.7% | $27.7M-43.6% | $49.2M-4.6% | $51.6M+97.3% | $26.1M+96.1% | $13.3M+85.0% | $7.2M | N/A |
| Operating Income | N/A | -$26.6M+36.8% | -$42.0M-44.1% | -$29.2M+15.8% | -$34.6M-28.4% | -$27.0M-39.8% | -$19.3M+57.5% | -$45.4M-68.9% | -$26.9M+68.1% | -$84.3M-4.1% | -$81.0M-12.5% | -$72.0M-50.2% | -$47.9M-64.5% | -$29.1M-115.3% | -$13.5M | N/A |
| Interest Expense | N/A | $207K-84.3% | $1.3M-9.2% | $1.4M-10.4% | $1.6M+26.2% | $1.3M | $0 | N/A | $134K-53.5% | $288K | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A | $67K-66.7% | $201K+168.0% | $75K | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$26.3M+37.2% | -$41.8M-41.9% | -$29.5M+17.4% | -$35.7M-26.2% | -$28.3M-47.3% | -$19.2M+56.9% | -$44.6M-63.9% | -$27.2M+67.8% | -$84.6M-2.8% | -$82.3M-12.3% | -$73.2M-47.9% | -$49.5M-70.5% | -$29.0M-115.0% | -$13.5M | N/A |
| EPS (Diluted) | — | -$6.33 | -$19.50 | -$1.91 | -$3.09 | -$7.47 | -$41.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TPST Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.9M-59.2% | $41.5M-19.6% | $51.6M+12.0% | $46.1M-37.1% | $73.2M+220.3% | $22.9M-69.5% | $75.0M-10.8% | $84.1M+324.4% | $19.8M-83.8% | $122.5M-11.6% | $138.6M+111.4% | $65.6M+37.9% | $47.5M+44.9% | $32.8M+615.7% | $4.6M |
| Current Assets | $8.3M-73.7% | $31.5M-22.0% | $40.4M+22.5% | $33.0M-52.2% | $69.0M+247.9% | $19.8M-72.1% | $71.1M-14.7% | $83.4M+322.6% | $19.7M-83.0% | $116.4M-10.3% | $129.9M+109.9% | $61.9M+37.3% | $45.1M+41.0% | $32.0M+597.2% | $4.6M |
| Cash & Equivalents | $7.7M-74.5% | $30.3M-22.8% | $39.2M+25.6% | $31.2M-39.7% | $51.8M+175.4% | $18.8M-69.9% | $62.5M-14.7% | $73.3M+316.9% | $17.6M-60.0% | $43.9M+1.6% | $43.2M+573.9% | $6.4M-64.5% | $18.1M+22.3% | $14.8M+225.4% | $4.5M |
| Total Liabilities | $10.3M-54.1% | $22.4M-10.0% | $24.8M-11.2% | $28.0M-24.6% | $37.1M-59.5% | $91.7M-26.9% | $125.3M+1044.4% | $11.0M-92.7% | $150.5M+950.7% | $14.3M+21.8% | $11.8M+14.8% | $10.2M+75.3% | $5.8M+179.2% | $2.1M-69.9% | $7.0M |
| Current Liabilities | $3.3M-76.7% | $14.2M+51.1% | $9.4M+29.3% | $7.3M-63.7% | $20.0M+521.5% | $3.2M-74.3% | $12.5M+27.5% | $9.8M+140.0% | $4.1M-69.0% | $13.2M+17.5% | $11.2M+10.5% | $10.2M+76.2% | $5.8M+176.8% | $2.1M+209.0% | $675K |
| Long-Term Debt | N/A | $0-100.0% | $6.3M-39.6% | $10.4M-31.2% | $15.1M | $0-100.0% | $168K-56.1% | $383K-36.1% | $599K | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.7M-65.1% | $19.1M-28.5% | $26.8M+47.8% | $18.1M-49.9% | $36.1M+152.5% | -$68.8M-36.6% | -$50.4M-171.0% | $71.0M+154.3% | -$130.7M-220.8% | $108.2M-14.7% | $126.8M+129.3% | $55.3M+32.7% | $41.7M+35.7% | $30.7M+1392.4% | -$2.4M |
| Retained Earnings | -$233.4M-12.7% | -$207.1M-25.3% | -$165.3M-21.7% | -$135.8M-35.7% | -$100.1M-39.4% | -$71.8M+65.6% | -$208.7M-27.2% | -$164.1M-19.9% | -$136.9M+45.3% | -$250.2M-49.0% | -$167.9M-77.3% | -$94.7M-109.6% | -$45.2M-180.0% | -$16.1M-514.9% | -$2.6M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
TPST Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.7M | -$26.8M+18.8% | -$33.0M-20.7% | -$27.4M+12.0% | -$31.1M-19.7% | -$26.0M-36.5% | -$19.0M+53.9% | -$41.2M-74.3% | -$23.6M-16.3% | -$20.3M+67.1% | -$61.7M-22.8% | -$50.3M-64.4% | -$30.6M-69.1% | -$18.1M-62.2% | -$11.2M | N/A |
| Capital Expenditures | $0 | $0-100.0% | $435K+155.9% | $170K-69.8% | $562K+316.3% | $135K+170.0% | $50K-87.4% | $397K+1002.8% | $36K+800.0% | $4K-99.8% | $2.6M-50.5% | $5.2M+86.5% | $2.8M+290.0% | $719K-15.3% | $849K | N/A |
| Free Cash Flow | -$20.7M | -$26.8M+19.8% | -$33.5M-21.6% | -$27.5M+13.0% | -$31.6M-21.2% | -$26.1M-36.8% | -$19.1M+54.2% | -$41.6M-75.7% | -$23.7M-16.4% | -$20.3M+68.4% | -$64.3M-15.9% | -$55.5M-66.3% | -$33.4M-77.5% | -$18.8M-56.7% | -$12.0M | N/A |
| Investing Cash Flow | $0 | $0+100.0% | -$435K-155.9% | -$170K+69.8% | -$562K-479.4% | -$97K-1516.7% | -$6K-100.2% | $4.0M+106.4% | $1.9M+321.8% | $458K-94.5% | $8.3M+121.7% | -$38.3M-16.8% | -$32.8M-197.6% | -$11.0M | N/A | N/A |
| Financing Cash Flow | $7.2M | $4.3M-82.6% | $24.5M-31.2% | $35.6M+212.2% | $11.4M-80.7% | $59.1M+70.7% | $34.6M+28.4% | $26.9M-65.3% | $77.7M+1842.0% | -$4.5M-108.2% | $54.1M-56.8% | $125.4M+142.5% | $51.7M+59.5% | $32.4M | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TPST Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -167.8% | -727.1% | -711.9% | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -28585.1% | -12406.1% | -25992.4% | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -28670.5% | -12597.2% | -26432.9% | N/A | N/A | N/A | N/A |
| Return on Equity | -393.8%-175.1pp | -218.8%-108.6pp | -110.2%+87.0pp | -197.2%-118.8pp | -78.4% | N/A | N/A | -38.3% | N/A | -76.0%-18.3pp | -57.7%+31.8pp | -89.5%-19.9pp | -69.7%-25.7pp | -44.0% | N/A |
| Return on Assets | -155.1%-54.3pp | -100.9%-43.7pp | -57.1%+20.3pp | -77.5%-38.8pp | -38.6%+45.4pp | -84.0%-24.6pp | -59.5%-27.1pp | -32.3%+394.6pp | -426.9%-359.8pp | -67.1%-14.3pp | -52.8%+22.7pp | -75.5%-14.4pp | -61.1%-19.9pp | -41.2% | N/A |
| Current Ratio | 2.50+0.3x | 2.21-2.1x | 4.29-0.2x | 4.53+1.1x | 3.44-2.7x | 6.15+0.5x | 5.68-2.8x | 8.50+3.7x | 4.82-4.0x | 8.82-2.7x | 11.55+5.5x | 6.08-1.7x | 7.81-7.5x | 15.32+8.5x | 6.79 |
| Debt-to-Equity | 1.54+1.5x | 0.00-0.2x | 0.23-0.3x | 0.57+0.2x | 0.42 | N/A | N/A | 0.01 | N/A | 0.130.0x | 0.09-0.1x | 0.190.0x | 0.14+0.1x | 0.07 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6896.3% | -9849.9% | -20041.5% | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Tempest Therapeutics Inc Ranks
Frequently Asked Questions
Is Tempest Therapeutics Inc profitable?
No, Tempest Therapeutics Inc (TPST) reported a net income of -$26.3M in fiscal year 2025.
What is Tempest Therapeutics Inc's EBITDA?
Tempest Therapeutics Inc (TPST) had EBITDA of -$26.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Tempest Therapeutics Inc's return on equity (ROE)?
Tempest Therapeutics Inc (TPST) has a return on equity of -393.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Tempest Therapeutics Inc's free cash flow?
Tempest Therapeutics Inc (TPST) recorded an outflow of $26.8M in free cash flow during fiscal year 2025. This represents a 19.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tempest Therapeutics Inc's operating cash flow?
Tempest Therapeutics Inc (TPST) recorded an outflow of $26.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Tempest Therapeutics Inc's total assets?
Tempest Therapeutics Inc (TPST) had $16.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Tempest Therapeutics Inc's capital expenditures?
Tempest Therapeutics Inc (TPST) reported no capital expenditure during fiscal year 2025.
How much does Tempest Therapeutics Inc spend on research and development?
Tempest Therapeutics Inc (TPST) invested $12.6M in research and development during fiscal year 2025.
What is Tempest Therapeutics Inc's current ratio?
Tempest Therapeutics Inc (TPST) had a current ratio of 2.50 as of fiscal year 2025, which is generally considered healthy.
What is Tempest Therapeutics Inc's debt-to-equity ratio?
Tempest Therapeutics Inc (TPST) had a debt-to-equity ratio of 1.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tempest Therapeutics Inc's return on assets (ROA)?
Tempest Therapeutics Inc (TPST) had a return on assets of -155.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Tempest Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Tempest Therapeutics Inc (TPST) held $7.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $26.8M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Tempest Therapeutics Inc's Piotroski F-Score?
Tempest Therapeutics Inc (TPST) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tempest Therapeutics Inc's earnings high quality?
Tempest Therapeutics Inc (TPST) reported a net loss of $26.3M while operations used $26.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Tempest Therapeutics Inc cover its interest payments?
Tempest Therapeutics Inc (TPST) reported an operating loss of $26.6M against $207K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.